share_log

Barclays Maintains Overweight on Arcus Biosciences, Lowers Price Target to $25

Benzinga ·  Jul 9 03:59

Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $35 to $25.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment